These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 10698601

  • 21. Body composition, endocrine and metabolic profiles in adults with Prader-Willi syndrome.
    Sode-Carlsen R, Farholt S, Rabben KF, Bollerslev J, Schreiner T, Jurik AG, Christiansen JS, Höybye C.
    Growth Horm IGF Res; 2010 Jun; 20(3):179-84. PubMed ID: 20199883
    [Abstract] [Full Text] [Related]

  • 22. Prader-Labhart-Willi syndrome: auxological response to a conventional dose of growth hormone in patients with classical growth hormone deficiency.
    Schmidt H, Bechtold S, Schwarz HP.
    Eur J Med Res; 2000 Jul 19; 5(7):307-10. PubMed ID: 10903191
    [Abstract] [Full Text] [Related]

  • 23. Growth hormone therapy for Prader-Willi syndrome: a critical appraisal.
    Allen DB, Carrel AL.
    J Pediatr Endocrinol Metab; 2004 Sep 19; 17 Suppl 4():1297-306. PubMed ID: 15506076
    [Abstract] [Full Text] [Related]

  • 24. Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database).
    Craig ME, Cowell CT, Larsson P, Zipf WB, Reiter EO, Albertsson Wikland K, Ranke MB, Price DA, KIGS International Board.
    Clin Endocrinol (Oxf); 2006 Aug 19; 65(2):178-85. PubMed ID: 16886957
    [Abstract] [Full Text] [Related]

  • 25. Skeletal muscle characteristics and motor performance after 2-year growth hormone treatment in adults with prader-willi syndrome.
    Lafortuna CL, Minocci A, Capodaglio P, Gondoni LA, Sartorio A, Vismara L, Rizzo G, Grugni G.
    J Clin Endocrinol Metab; 2014 May 19; 99(5):1816-24. PubMed ID: 24471571
    [Abstract] [Full Text] [Related]

  • 26. Changes in body composition during 12 months after discontinuation of growth hormone therapy in young adults with growth hormone deficiency from childhood.
    Stouthart PJ, de Ridder CM, Rekers-Mombarg LT, van der Waal HA.
    J Pediatr Endocrinol Metab; 1999 Apr 19; 12 Suppl 1():335-8. PubMed ID: 10698598
    [Abstract] [Full Text] [Related]

  • 27. Bone mineral density and body composition in adolescents with childhood-onset growth hormone deficiency.
    Boot AM, van der Sluis IM, Krenning EP, de Muinck Keizer-Schrama SM.
    Horm Res; 2009 Apr 19; 71(6):364-71. PubMed ID: 19506395
    [Abstract] [Full Text] [Related]

  • 28. Eight years of growth hormone treatment in children with Prader-Willi syndrome: maintaining the positive effects.
    Bakker NE, Kuppens RJ, Siemensma EP, Tummers-de Lind van Wijngaarden RF, Festen DA, Bindels-de Heus GC, Bocca G, Haring DA, Hoorweg-Nijman JJ, Houdijk EC, Jira PE, Lunshof L, Odink RJ, Oostdijk W, Rotteveel J, Schroor EJ, Van Alfen AA, Van Leeuwen M, Van Pinxteren-Nagler E, Van Wieringen H, Vreuls RC, Zwaveling-Soonawala N, de Ridder MA, Hokken-Koelega AC.
    J Clin Endocrinol Metab; 2013 Oct 19; 98(10):4013-22. PubMed ID: 24001750
    [Abstract] [Full Text] [Related]

  • 29. Sustained benefits of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome are dose-dependent.
    Carrel AL, Myers SE, Whitman BY, Allen DB.
    J Pediatr Endocrinol Metab; 2001 Oct 19; 14(8):1097-105. PubMed ID: 11592566
    [Abstract] [Full Text] [Related]

  • 30. Response to growth hormone treatment in Prader-Willi syndrome: auxological criteria versus genetic diagnosis.
    Scheermeyer E, Hughes I, Harris M, Ambler G, Crock P, Verge CF, Craig ME, Bergman P, Werther G, van Driel M, Davies PS, Choong CS.
    J Paediatr Child Health; 2013 Dec 19; 49(12):1045-51. PubMed ID: 23781979
    [Abstract] [Full Text] [Related]

  • 31. Growth hormone treatment improves body composition in adults with Prader-Willi syndrome.
    Höybye C, Hilding A, Jacobsson H, Thorén M.
    Clin Endocrinol (Oxf); 2003 May 19; 58(5):653-61. PubMed ID: 12699450
    [Abstract] [Full Text] [Related]

  • 32. The efficacy and safety of long-term Norditropin® treatment in children with Prader-Willi syndrome.
    Meinhardt U, Christiansen JS, Farholt S, Lämmer C, Ostergaard JR, Schmidt F, Kappelgaard AM, Eiholzer U.
    Horm Metab Res; 2013 Jul 19; 45(7):532-6. PubMed ID: 23632904
    [Abstract] [Full Text] [Related]

  • 33. Effect of 6 months of growth hormone treatment in young children with Prader-Willi syndrome.
    Eiholzer U, Weber R, Stutz K, Steinert H.
    Acta Paediatr Suppl; 1997 Nov 19; 423():66-8. PubMed ID: 9401543
    [Abstract] [Full Text] [Related]

  • 34. Dietary Energy Intake, Body Composition and Resting Energy Expenditure in Prepubertal Children with Prader-Willi Syndrome before and during Growth Hormone Treatment: A Randomized Controlled Trial.
    Bakker NE, Siemensma EP, Koopman C, Hokken-Koelega AC.
    Horm Res Paediatr; 2015 Nov 19; 83(5):321-31. PubMed ID: 25764996
    [Abstract] [Full Text] [Related]

  • 35. Long-term effects of growth hormone therapy on patients with Prader-Willi syndrome.
    Sipilä I, Sintonen H, Hietanen H, Apajasalo M, Alanne S, Viita AM, Leinonen E.
    Acta Paediatr; 2010 Nov 19; 99(11):1712-8. PubMed ID: 20545932
    [Abstract] [Full Text] [Related]

  • 36. Body composition abnormalities in children with Prader-Willi syndrome and long-term effects of growth hormone therapy.
    Eiholzer U, l'Allemand D, van der Sluis I, Steinert H, Gasser T, Ellis K.
    Horm Res; 2000 Nov 19; 53(4):200-6. PubMed ID: 11044804
    [Abstract] [Full Text] [Related]

  • 37. Growth hormone therapy improves exercise capacity in adult patients with Prader-Willi syndrome.
    Gondoni LA, Vismara L, Marzullo P, Vettor R, Liuzzi A, Grugni G.
    J Endocrinol Invest; 2008 Sep 19; 31(9):765-72. PubMed ID: 18997487
    [Abstract] [Full Text] [Related]

  • 38. Beneficial Effects of GH in Young Adults With Prader-Willi Syndrome: A 2-Year Crossover Trial.
    Kuppens RJ, Bakker NE, Siemensma EP, Tummers-de Lind van Wijngaarden RF, Donze SH, Festen DA, van Alfen-van der Velden JA, Stijnen T, Hokken-Koelega AC.
    J Clin Endocrinol Metab; 2016 Nov 19; 101(11):4110-4116. PubMed ID: 27552545
    [Abstract] [Full Text] [Related]

  • 39. Effect of short-term therapy with recombinant human growth hormone (GH) on metabolic parameters and preclinical atherosclerotic markers in hypopituitary patients with growth hormone deficiency.
    Benedini S, Dalle Carbonare L, Albiger N, Scanarini M, Bilora F, Petrobelli F, Giannini S, Mantero F, Scaroni C.
    Horm Metab Res; 2006 Jan 19; 38(1):16-21. PubMed ID: 16477535
    [Abstract] [Full Text] [Related]

  • 40. Endocrine dysfunction in Prader-Willi syndrome: a review with special reference to GH.
    Burman P, Ritzén EM, Lindgren AC.
    Endocr Rev; 2001 Dec 19; 22(6):787-99. PubMed ID: 11739333
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.